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Impact of metformin on peak aerobic capacity
Barry Braun, Pamela Eze, Brooke R. Stephens, Todd A. Hagobian,
Carrie G. Sharoff, Stuart R. Chipkin, and Benjamin Goldstein

Abstract: Individually, exercise and the drug metformin have been shown to prevent or delay type 2 diabetes. Metformin
mildly inhibits complex I of the electron transport system and may impact aerobic capacity in people exercising while tak
ing metformin. The purpose of the study was to evaluate the effects of metformin on maximal aerobic capacity in healthy
individuals without mitochondrial dysfunction. Seventeen healthy, normal-weight men (n = 11) and women (n = 6) partici
pated in a double-blind, placebo-controlled, cross-over design. Peak aerobic capacity was measured twice using a continu
ous, incrementally graded protocol; once after 7–9 d of metformin (final dose = 2000 mg/d) and once with placebo, with
1 week between tests. The order of the conditions was counterbalanced. Peak oxygen uptake (VO2 peak), heart rate (HR),
ventilation (VE), respiratory exchange ratio (RER), rating of perceived exertion (RPE), and test duration were compared
across conditions using paired t tests with the R statistical program. VO2 peak (–2.7%), peak heart rate (–2.0%), peak ven
tilation (–6.2%), peak RER (–3.0%), and exercise duration (–4.1%) were all reduced slightly, but significantly, with
metformin (all p < 0.05). There was no effect of metformin on RPE or ventilatory breakpoint. Correlations between
the decrement in VO2 peak and any of the other outcome variables were weak (r2 < 0.20) and not significant. Shortterm treatment with metformin has statistically significant, but physiologically subtle, effects that reduce key outcomes
related to maximal exercise capacity. Whether this small but consistent effect is manifested in people with insulin re
sistance or diabetes who already have some degree of mitochondrial dysfunction remains to be determined.
Key words: pre-diabetes, type 2 diabetes, exercise, biguanide.
Résumé : Isolément, l’exercice physique et un médicament, la metformine, préviennent ou retardent l’apparition du dia
bète de type 2. La metformine inhibe légèrement le complexe I de la chaı̂ne respiratoire et peut avoir un effet sur la capa
cité aérobie des individus qui font de l’exercice physique. Le but de cette étude est d’évaluer l’effet de la metformine sur
la puissance aérobie maximale d’individus en bonne santé et sans troubles mitochondriaux. Six femmes et 11 hommes en
bonne santé et de poids normal participent à une étude expérimentale à double insu avec groupe témoin et inversion des
groupes. On mesure deux fois la puissance aérobie de pointe au moyen d’un test d’effort continu d’intensité croissante,
une fois après 7 à 9 jours de consommation de metformine (dose terminale, 2 000 mg par jour) et l’autre fois, à sept jours
d’écart, après avoir pris un placebo. L’ordre des séances d’évaluation est contrebalancé. Au moyen du programme
d’analyse statistique R, on compare par des tests t pour mesures appariées les variables suivantes observées dans les deux
conditions : la consommation d’oxygène (VO2) de pointe, la fréquence cardiaque (HR), le débit ventilatoire (VE), le ratio
d’échanges gazeux (RER), la perception de l’intensité de l’effort (RPE) et la durée du test. La metformine suscite des di
minutions légères mais significatives (p < 0,05) des variables suivantes : le VO2 de pointe (–2,7 %), la fréquence cardiaque
de pointe (–2,0 %), le débit ventilatoire de pointe (–6,2 %), le RER de pointe (–3,0 %) et la durée du test (–4,1 %). La
metformine n’au aucun effet sur la RPE et sur le seuil ventilatoire. La corrélation entre la diminution du VO2 de pointe et
n’importe laquelle des autres variables est faible et non significative (r2 < 0,20). L’administration à court terme de la met
formine suscite des effets significatifs, mais faibles sur les variables associées à la capacité d’effort aérobie. Il reste à dé
terminer si ces effets manifestes quoique faibles s’observent chez des individus insulinorésistants ou souffrant du diabète,
mais qui ont des troubles mitochondriaux.
Mots-clés : prédiabète, diabète de type 2, exercice physique, biguanide.
[Traduit par la Rédaction]

Introduction
The results from the Diabetes Prevention Program (DPP)
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and other similar interventions show that lifestyle interven
tion (i.e., modification of diet and physical activity) is remarkably effective in preventing and (or) delaying the
transition from insulin resistance to diabetes. (Knowler et
al. 2002; Orchard et al. 2005; Pan et al. 1997; Tuomilehto
et al. 2001). In response, a tremendous effort is being made
to increase participation in physical activity among overweight, sedentary individuals (Bethel and Califf 2007;
Dasgupta et al. 2006; Hamman et al. 2006; Kriska et al.
2006; Manson and Spelsberg 1994). The DPP also showed
that the commonly prescribed biguanide drug metformin
also significantly delayed or prevented the transition from
impaired glucose metabolism to a diagnosis of diabetes
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(Knowler et al. 2002; Orchard et al. 2005). In addition to
being one of the most commonly prescribed drugs to treat
individuals with overt diabetes, metformin is also increas
ingly prescribed before the diagnosis of diabetes to forestall
the transition to diabetes in high-risk individuals (Anderson
2005; De Lusignan et al. 2005; Matthaei et al. 2000). Indi
viduals prescribed metformin are also encouraged to be
physically active. For many overweight or obese men and
women, the additive effects of increased physical activity
and metformin can be viewed as a promising combination
therapy.
Several in vitro studies have shown that metformin has an
inhibitory effect on the activity of complex I (transfer of
electrons from NADH to coenzyme Q10) of the mitochondrial
electron transport system (Batandier et al. 2006; El-Mir et al.
2000; Guigas et al. 2004; Leverve et al. 2003; Owen et al.
2000). Inhibition of complex I may slow the transfer of re
ducing equivalents from the tricarboxylic acid cycle and po
tentially limit the capacity for oxidative metabolism
(although there is some reserve mitochondrial capacity to
use oxygen during exercise with large muscle groups). If the
inhibition of complex I exceeds that extra capacity, the prac
tical implication would be a lowering of maximal cardiores
piratory capacity and increased relative intensity at any given
absolute exercise workload. Perception of effort would be in
creased; potentially affecting exercise intensity, duration, to
tal energy expenditure, and behavior. In studies of aerobic
exercise physiology or behavior, the exercise intensity is al
most always controlled by scaling it as a percentage of max
imal aerobic capacity (Braun et al. 2004; Goodpaster et al.
2002; Houmard et al. 2004; Musi and Goodyear 2006). If
metformin treatment lowers peak oxygen uptake (VO2 peak),
correct comparison of any outcome variables between the
metformin and placebo groups will be confounded by the dif
ferent relative exercise intensity in each condition.
Several laboratory groups are conducting research studies
in which the addition of exercise to metformin therapy is
being tested for efficacy in improving glucose metabolism
(Hallsten et al. 2002; Smith et al. 2007; Tang and Reed
2001), as well as non-glycemic targets such as microvascu
lar function (Jadhav et al. 2006) and cardiovascular indices
in patients with HIV (Driscoll et al. 2004). The converse,
whether treatment with metformin impacts exercise capacity,
has not been considered in any systematic way. The ques
tion is relevant because a reduction in VO2 peak caused by
metformin may affect functional exercise capacity and im
pact compliance with physical activity guidelines.
Therefore, it is important from both a clinical and experi
mental perspective to understand whether or not treatment
with metformin affects exercise capacity. The purpose of
the present study was to assess whether short-term treatment
with the typical clinical dose of metformin impacted maxi
mal oxygen consumption and related variables (e.g., maxi
mal ventilation (VE), heart rate (HR), respiratory exchange
ratio (RER), etc.) relative to a placebo. To understand the
effects of metformin uncomplicated by the dysfunction in
mitochondria or oxidative metabolism that is strongly
associated with insulin resistance and type 2 diabetes
(Regensteiner et al. 1998; Lowell and Shulman 2005; Ritov
et al. 2005), the study was conducted in healthy people with
normal glucose metabolism.
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Materials and methods
Overview
The study was conducted using a longitudinal, placebocontrolled design in which subjects served as their own con
trols. Subjects performed a test of peak aerobic capacity
twice; once while treated with metformin (1000 mg, twice
daily) and once with placebo. There were 7 days between
tests to allow sufficient washout of metformin (the half-life
for elimination of metformin is 2–6 h). The order in which
the treatment of placebo and metformin conditions were
completed was counterbalanced across subjects. VO2 peak
and related variables (e.g., VE, HR, RER, etc.) were com
pared across the metformin and placebo conditions.
Subjects
A convenience sample of 18 locally available non-diabetic
men (n = 11) and women (n = 7) participated in the study
(Table 1). All subjects signed an informed consent docu
ment and completed a physical activity readiness question
naire and a health history prior to initiating testing. All
subjects were in good overall health, normal weight or
overweight, but not obese (body mass index (BMI) = 21–29),
and did not use tobacco products or take any medications
(e.g., other antihyperglycemic agents, statin drugs, betablockers, diuretics, etc.) or dietary supplements (e.g., chro
mium, vanadium, niacin, etc.) that could potentially inter
act with metformin and (or) maximal cardiorespiratory
capacity. To maximize the generalizability of the data
across fitness levels, a mix of relatively sedentary and rec
reationally active men and women were recruited. The
study was approved by the Institutional Review Board at
the University of Massachusetts (Amherst, Mass.) prior to
initiation of the study. One woman dropped out of the
study due to gastrointestinal problems in response to the
pharmacological treatment. Therefore the final sample size
consisted of 17 subjects (11 men, 6 women).
Study design
VO2 peak was determined using an incremental treadmill
protocol on either a treadmill (Lifestride 9100, Life Fitness,
Schiller Park, Ill.) or a cycle Ergometer (Sensormedics 800,
Yorba Linda, Calif.) according to subject preference. For
each individual subject, the placebo and metformin tests
were always conducted at the same time of day, with no ex
ercise for 24 h and no food for 3 h before each test. Testing
commenced at a relatively easy submaximal workload that
was scaled to each subject’s fitness or training status (range
of 50–150 W on the cycle ergometer and 4–6 miles/h
(1 mile = 1.6 km) at 0% grade on the treadmill). Either the
cycle resistance (25–50 W increments in early stages; 25 W
increments as test progressed beyond first few stages) or
treadmill grade (+2% increments) was increased every
2 min until a maximal voluntary effort was achieved. Respi
ratory gases from collected air were measured using the
TrueMax2400 Metabolic Measurement System (Parvo
medics, Salt Lake City, Utah). Heart rate was monitored
throughout testing using a Polar Advantage Heart Rate Mon
itor (Polar Inc., Lake Success, N.Y.). Fifteen seconds before
the end of each stage, a systemic rating of perceived exer
tion (RPE) was assessed by having subjects point to a num
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Table 1. Subject characteristics (n = 17).

Mean±SD

Age (y)
27.9±3.3

Height (cm)
174.0±9.2

Body mass (kg):
placebo
71.2±15.1

Body mass (kg):
metformin
71.1±14.4

BMI (kg�m–2)
24.1±3.6

Note: Descriptive data shown are mean and standard deviation for 11 men and 6 women who completed the
study.

Statistical analysis
Data are presented as condition mean, the difference be
tween conditions, 95% confidence interval of that differ
ence, and exact p value except where noted. Statistical
significance of the differences between conditions was
tested using Student’s paired t test. The � level was set at
0.05. Correlations between outcome variables of interest
were assessed using Pearson product–moment correlation.

After this point, unequal sample sizes (due to subjects end
ing the test at different times in the metformin or placebo
conditions) limit direct comparison by time. VO2 peak, how
ever, whether assessed in absolute volume or scaled to body
mass, was slightly (–2.7%) but significantly lower with met
formin treatment compared with placebo (Table 2). Relative
to placebo, VO2max on metformin was lower in 12 of 17 sub
jects, unchanged in 3, and higher in 2. Similarly, peak HR
(–2.0%), VE (–6.2%), and RER (–3.0%) were all reduced
slightly in the metformin condition (Table 2). Subjects
were unable to continue exercising after 13 min 56 s in the
metformin condition compared with 14 min 31 s with pla
cebo (–4.1%). Nine of the 17 subjects attained a higher
workload during the placebo test (+30 W or +2% grade)
relative to the metformin test.
Although all of the outcome variables declined signifi
cantly in the metformin condition, correlations between
the change in maximal oxygen consumption and any other
outcome variable were very weak with correlation coeffi
cients all r2 < 0.20 and p > 0.30. The magnitude of the
change in VO2 peak induced by metformin was also not
strongly correlated with cardiorespiratory fitness, i.e., the
baseline VO2 peak measured in millilitres per kilogram per
minute (mL�kg–1�min–1). To better understand the relation
ships, we compared 9 metformin ‘‘responders’’, defined as
individuals in whom VO2 peak declined by more than
1.5 mL�kg–1�min–1 (mean = –3.5 mL�kg–1�min–1) when
taking metformin; with 6 ‘‘non-responders’’: defined as in
dividuals in whom VO2 peak declined by less than
0.5 mL�kg–1�min–1 (mean = +0.1 mL�kg–1�min–1) when tak
ing metformin. There were no significant differences in the
decrement in maximal HR (–6.4 beats�min–1 for responders
vs. –5.0 beats�min–1 for non-responders), ventilation
(–9.9 L�min–1 for responders vs. –7.8 L�min–1 for nonresponders), or test duration (–32 s for responders vs. –49 s
for nonresponders). Similarly, of 8 subjects who reached a
lower maximal workload when taking metformin, VO2 peak
was lower (>1.0 mL�kg–1�min–1) in only 5. Conversely, in
9 subjects who reached the same maximal workload when
taking metformin, VO2 peak was depressed by more than
1 mL�kg–1�min–1 in 6 of them.
Estimated ventilatory breakpoint occurred at almost exactly
the same VO2 in both conditions (data not shown). Because
VO2 peak was lower with metformin, estimated VBP occurred
at a slightly higher %VO2 peak with metformin (Table 2), but
the difference between means was not significant.

Results

Discussion

VO2, HR, VE,RER, and RPE over time are shown in
Figs. 1a–1e). For the initial 11 min of the test, the slope of
the relationships between outcome and time were virtually
indistinguishable in the metformin and placebo conditions.

Summary of results
There was a significant reduction in maximal aerobic ca
pacity when healthy, normal-weight subjects were tested
while treated with a typical clinical dose of metformin as

ber on a visual ordinal scale ranging from 6 (no exertion at
all) to 20 (maximal exertion). Oxygen consumption was
considered peak upon attainment of at least 2 of the follow
ing 3 criteria: increase in VO2 less than 150 mL despite in
creased workload, RER > 1.10, and HR within 15 beats�min–1
of age-predicted maximal heart rate (HRmax = 220 – age (in
years)). Ventilatory breakpoint (VBP), the first inflection
point at which ventilation increases more rapidly than oxygen
consumption (sometimes referred to as ‘‘anaerobic thresh
old’’), was estimated visually from the relationship between
VO2 and VE and the relationship between VCO2 and VE.
When the two relationships are plotted on the same axes, the
point at which the 2 curves reach a crossing point is defined
as the VBP (BroÞaitienë and Jakumaitë 2002; Cohen-Solal et
al. 1991). One individual, blinded to the experimental condi
tions, estimated the VBP for each subject in each experimen
tal condition.
Metformin and placebo treatment
Metformin treatment began at 500 mg/d and was in
creased every second day to reach the standard clinical
dose, 1000 mg twice daily. In most subjects, this dose was
attained on day 5 or 6, but in men or women who experi
enced gastrointestinal symptoms (n = 3), the ramp-up period
was extended for up to 3 more days. Once attaining the final
dosage, all subjects continued on that dose for 3 consecutive
days. Placebo treatment was identical but all subjects were
able to reach the final dose on day 5. Although it was de
signed to be a double-blind protocol, the presence of a met
allic taste in the mouth and (or) gastrointestinal symptoms
alerted several subjects (these side-effects were listed in the
informed consent document as per IRB requirements) and
the investigators to which treatment was being given. De
spite this limitation, only a few subjects were reasonably
certain which treatment they had been given and several
were convinced they had metformin when they actually had
the placebo.
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Fig. 1. Oxygen consumption (a), heart rate (b), ventilation (c), respiratory exchange ratio (d), and rating of perceived exertion (e) over time
during the maximal exercise test. Owing to different exercise durations across conditions, the full data set (n = 17) can only be compared
during minutes 2–11 and at the end of the test. The label ‘‘max’’ denotes the end of the incremental test; mean = 14.52 min for placebo and
13.92 min for metformin.
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Placebo
Metformin
� (95% CI)
p value

Note: �, difference between condition means; HR, heart rate; VE, ventilation; RER, respiratory exchange ratio; VBP, ventilatory breakpoint.
*p < 0.05.

Max HR
(beats�min–1)
187.3±2.4
183.5±2.5
3.8 (2.8–4.8)
6.6 (4.5–8.7)
VO2 peak
(mL�kg–1�min–1)
49.96±2.53
48.66±2.56
1.27 (0.75–1.82)
0.026*
VO2 peak
(L�min–1)
3.63±0.29
3.53±0.29
0.09 (0.05–0.14)
0.026*

Table 2. Comparison of outcome variables across the two conditions.

Max VE
(L�min–1)
108.0±7.8
101.4±7.4
0.001*
0.006*

Max RER
1.184±0.015
1.149±0.016
0.035 (0.021–0.049)
0.008*

Duration of test (min)
14.52±0.67
13.92±0.63
0.60 (0.42–0.80)
0.005*

Estimated VBP
(% VO2 peak)
71.2±3.9
74.5±4.3
3.3 (–1.5–+8.1)
0.512
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Physiological relevance
The decline in maximal cardiorespiratory capacity with
metformin treatment was statistically significant but, on
average, physiologically subtle. Although a 3% decline
might be critical to the performance of an elite endurance
athlete, it is unlikely to be of concern to the individual doing
recreational physical activity to enhance health. Some indi
viduals responded more robustly to the metformin treatment,
however, with declines in VO2 peak of up to 10%. A decline
of that magnitude can be the difference between exercising
below or above the lactate threshold, perceived exertion
would be noticeably higher, and time to fatigue would be re
duced. The real-world impact of metformin treatment on ex
ercise capacity will depend on how the effects manifest over
time. The antihyperglycemic effects of metformin manifest
quickly and longer-term treatment does not confer increas
ing benefits (although metformin-associated weight loss can
potentiate the direct effects). If the metformin effect on car
diorespiratory capacity we observed is transient, there may
be no impairments that last beyond the first week. Con
versely, if the impact of metformin on cardiorespiratory fit
ness is maintained or potentiated with longer-term treatment,
exercise capacity could be impacted more severely. Edu
cated speculation would be aided by understanding how
metformin caused the decline in VO2 peak observed in the
present study.
Mechanisms
All of the associated outcomes (maximal HR, VE, test
duration, etc.) declined similarly, suggesting that individu
als simply did not exercise ‘‘to their maximum’’ when
treated with metformin. However, there was no difference
between conditions in the final workload attained. Further
more, there were no associations between exercise duration
and any of the other outcomes. Lastly, maximal HR, VE,
and exercise duration were not different in the individuals
who had a large decline in VO2 peak with metformin (de
cline in VO2 peak > 1.5 mL�kg–1�min–1) vs. those who did
not (decline < 0.5 mL�kg–1�min–1). To illustrate the point,
the individual with the largest absolute decline in VO2 peak
(–6.5 mL�kg–1�min–1) had the same exercise duration and
reached the same maximal workload on both tests. Con
versely, the person with the largest decline in duration
(placebo, 17.27 min; metformin, 15.50 min.) had no change
in VO2 peak.
There are several potential explanations for the finding
that metformin had a slight lowering effect on VO2 peak, HR,
VE, and RER. According to several studies, all performed
using in vitro cell systems, metformin could impair VO2 peak
by inhibiting the mitochondrial electron transport system
(Batandier et al. 2006; El-Mir et al. 2000; Guigas et al.
2004; Leverve et al. 2003; Owen et al. 2000). The inhibition
has been observed in skeletal muscle (Brunmair et al. 2004),
isolated liver (Batandier et al. 2006; El-Mir et al. 2000;
Leverve et al. 2003; Owen et al. 2000,) and tumor cells
(Guigas et al. 2004). Effects of metformin on skeletal
muscle and (or) cardiac tissue have not been studied to
date. In liver cells, oxidation of malate or aspartate, but not
succinate, is impaired, implying that inhibition of mitochon
drial respiration is specific to complex 1 (Owen et al. 2000).
In one study, metformin lessened production of reactive
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oxygen species by reverse electron transport (Batandier et
al. 2006). Researchers have speculated that the inhibition of
complex I may not be a pharmacological ‘‘side effect’’, but
is instead central to the (currently still unclear) metformin
mechanism of action (Leverve et al. 2003; Owen et al.
2000). Inhibition of complex I by metformin in skeletal
muscle could constrain oxygen extraction (manifested as a
smaller arterial–venous difference in the partial pressure of
O2 (ppO2)) rather than oxygen delivery (cardiac output). If
the inhibition were also present in cardiac muscle then de
livery could also be constrained. There were no associations
between the changes in VO2 peak and maximal HR or VE;
even if there were, these gross measurements are inadequate
to determine whether VO2 peak declines because of limita
tions on oxygen delivery or extraction. Without assessing
cardiac output or mitochondrial ppO2, whether lower maxi
mal HR and VE impair VO2 peak or are a result of the lower
VO2 peak cannot be determined.
Inhibition of complex I would also be expected to con
strain oxidation of TCA cycle-derived reducing equivalents,
restrict oxidative metabolism of pyruvate and acetyl CoA,
and increase reliance on glycolytic metabolism to lactate.
Blood lactate was not measured in the present study, but
the lactate breakpoint can be estimated (although not neces
sarily causally related) from the ventilatory breakpoint, the
inflection point where ventilation rises more steeply than
oxygen consumption. Again, there was no difference in the
ventilatory breakpoint, suggesting that the balance between
oxidative and non-oxidative metabolism was not changed in
response to metformin.
Research and clinical implications
Although the subtle decrements in VO2 peak attributable to
metformin are unlikely to have important clinical relevance,
they are germane to study designs that involve exercise and
metformin treatment. Exercise intensity is usually based on
a percentage of VO2 peak (Braun et al. 2004; Goodpaster et
al. 2002; Houmard et al. 2004; Musi and Goodyear 2006),
therefore researchers need to measure VO2 peak while the
subject is on metformin or risk incorrectly setting the exer
cise intensity during the metformin treatment intervention.
Metformin is prescribed to manage hyperglycemia in indi
viduals with diabetes and prophylactically to delay the tran
sition to diabetes for individuals with elevated fasting
glucose (De Lusignan et al. 2005; Jadhav et al. 2006). The
healthy subjects used in the present study limits the applica
tion of the results to clinical populations. Healthy individu
als were tested to avoid the complication of underlying
mitochondrial myopathy or the confounding variable of hy
perglycemia. Whether maximal oxygen consumption would
change to a greater or lesser extent in people with diabetes
or insulin resistance is difficult to predict. In general,
cardiorespiratory fitness is lower in those individuals
compared to the men and women tested in the current study
(Regensteiner et al. 1998), but we saw no effects of baseline
fitness on the magnitude of the observed differences. When
matched for other confounding variables (e.g., body fat,
VO2 peak, habitual physical activity) blood glucose uptake
during exercise is the same between insulin-resistant and
insulin-sensitive individuals (Braun et al. 2004). To deter
mine whether the decrement in VO2 peak observed in non
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diabetic individuals will be exaggerated or attenuated in
those with insulin resistance or diabetes will require explic
itly testing the effects of metformin on aerobic capacity in
those individuals. The observation that VO2, VE, HR, and
RER were not affected by metformin at submaximal work
loads has clear practical relevance. The results imply that
exercise capacity is only affected at or near maximal
workloads. Therefore, it is unlikely that individuals would
experience any impairment in exercise tolerance at the ex
ercise intensities experienced by the great majority of rec
reationally active individuals.
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